Rinat Neuroscience

Rinat Neuroscience
Based: Palo Alto, CA
Founded: 2001

Why It's Fierce: When Rinat Neuroscience was spun off from Genentech four years ago, it took 15 years of promising work in protein therapies and two primary focuses: pain and Alzheimer's. It also kept Genentech -- a biotech pioneer currently on a big winning streak -- as a development partner. A pain medication is in Phase I/II trials with Genentech partnered up for development. Preclinical testing indicates a powerful antidote to post-operative and other pains. And there's research into an antibody that targets beta protein, which is believed to play a role in Alzheimer's. They're coming in behind Elan, which is in Phase II, but are banking on a better design and safety profile.

What to look for: Look for the initial clinical data on pain in November. But researchers still have a long way to go before it reaches any market, anticipated around 2011. Look for an IND in December with early stage human trials launched in early 2006.

Rinat Neuroscience

Suggested Articles

Horizon Therapeutics is expanding its U.S. footprint to the Bay Area—the company unveiled a new R&D and manufacturing site in South San Francisco.

Azeria Therapeutics has raised £32 million ($41 million) to take its estrogen receptor positive breast cancer program into the clinic.

Biogen’s Al Sandrock has given a bullish assessment of Alzheimer’s disease drug aducanumab. The head of R&D at Biogen thinks the drug works, despite i